Search results for "AGENTS"

showing 10 items of 7330 documents

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?

2012

Abstract Background Immunosuppressive therapy after orthotopic liver transplantation (OLT) requires a high degree of patient compliance to guarantee safety and avoid side effects. In 2007, prolonged-release tacrolimus was launched in Europe to improve compliance. In this prospective observational crossover single-center trial, we analyzed effects and side effects of prolonged-release tacrolimus in OLT patients. Methods LT patients at our center were included if they were older than l8 years of age, had had the procedure at least 6 months prior, and were outpatients currently on twice-daily tacrolimus. Patients were observed for 6 months before switching to once-daily tacrolimus. Patient his…

AdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentChemistry Pharmaceuticalchemical and pharmacologic phenomenaLiver transplantationGastroenterologyTacrolimuschemistry.chemical_compoundPharmacotherapyDiabetes mellitusInternal medicineGermanymedicineHumansMedical historyProspective StudiesProspective cohort studyAgedTransplantationCross-Over Studiesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseCrossover studyTacrolimusSurgeryLiver Transplantationsurgical procedures operativeTreatment OutcomechemistryDelayed-Action PreparationsSurgeryDrug Therapy CombinationFemaleGlycated hemoglobinbusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion

2003

Abstract Ischemic-type biliary lesions (ITBLs) lead to considerable morbidity after orthotopic liver transplantation (OLT). The exact pathogenesis is unknown. We tested the hypothesis that insufficient perfusion of biliary arterial vessels might be responsible for ITBLs. This could be prevented by improved perfusion techniques. Since February 2000, we performed a controlled study using arterial back-table pressure perfusion (AP) to achieve reliable perfusion of the biliary-tract capillary system, which may be impaired by the high viscosity of University of Wisconsin solution. We retrospectively analyzed 190 OLTs performed between September 1997 and July 2002 with regard to ITBLs. One hundre…

AdultGraft Rejectionmedicine.medical_specialtyAdenosineOrthotopic liver transplantationAllopurinolmedicine.medical_treatmentOrgan Preservation SolutionsUrologyLiver transplantationPathogenesisPostoperative ComplicationsRaffinosePressuremedicineHumansInsulinViaspanAlanine aminotransferaseAgedRetrospective StudiesTransplantationHepatologyViscositybusiness.industryLiver DiseasesGraft SurvivalImmunosuppressionMiddle AgedGlutathioneStandard techniqueLiver TransplantationSurgeryPerfusionSurvival RateReperfusion InjurySurgeryBile DuctsbusinessPerfusionImmunosuppressive AgentsLiver Transplantation
researchProduct

Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration.

2008

Introduction and Objectives. Primary graft dysfunction (PGD) following lung transplantation (LT) is associated with an activation of the inflammatory cascade and release of cytokines. Inhaled nitric oxide (iNO) provides specific pulmonary vasodilatation and improves oxygenation. Our objective was to verify whether administering iNO to LT patients modified the blood and bronchoalveolar lavage (BAL) interleukin (IL)-6 and -8 levels in the event of PGD. Materials and Methods. Thirty-two LT patients were randomized to the iNO treatment or the control group. Patients in the first group were given 10 ppm of iNO from the start of LT until 48 hours afterward. BAL and peripheral arterial blood sampl…

AdultGraft Rejectionmedicine.medical_specialtyAdolescentmedicine.medical_treatmentNitric OxideGastroenterologyNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsInternal medicineAdministration InhalationmedicineLung transplantationHumansInterleukin 6AgedInflammationTransplantationLungmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Interleukin-8Interleukinrespiratory systemMiddle AgedBronchodilator AgentsTransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiabiology.proteinArterial bloodSurgerybusinessLung TransplantationTransplantation proceedings
researchProduct

Uterus transplantation trial: 1-year outcome

2014

Objective To report the 12-month outcome of seven patients with viable uteri after uterus transplantation (UTx). Design Prospective observational study. Setting University hospital. Patient(s) Seven patients with absolute uterine infertility and viable uteri for 12 months after live-donor UTx. Intervention(s) Predetermined immunosuppression was with tacrolimus and mychophenolate mofetil (MMF) during 6 months, whereupon MMF should be withdrawn. Frequent ultrasound examinations were performed to assess uterine appearance and uterine artery blood flow. Cervical biopsies (for histological detection of rejection) were obtained at preset time points, with temporary adjustments of immunosuppressio…

AdultGraft Rejectionmedicine.medical_specialtymedicine.medical_treatmentUterusUrologyAzathioprineMenstruationsmedicine.arteryUterus transplantationHumansMedicineLongitudinal StudiesProspective StudiesUterine arterybusiness.industryUterusFertility PreservationObstetrics and GynecologyImmunosuppressionOrgan TransplantationTacrolimusSurgeryTransplantationTreatment Outcomemedicine.anatomical_structureReproductive MedicineFemalebusinessInfertility FemaleImmunosuppressive Agentsmedicine.drugFertility and Sterility
researchProduct

Treatment of Vaginal Trichomoniasis with a Single Dose of Tinidazole

1974

SummaryTwenty-two patients with proven vaginal trichomoniasis were treated with a single dose of 2 g. tinidazole. Twenty-one patients were cured, at both the early and the late follow-up visits. No side-effects were noted and no abnormalities of the clinical laboratory parameters were found in the trial. A historical comparison with published works was carried out and the results compared favourably with those found in the literature for tinidazole as well as for other agents used in a similar fashion.

AdultGynecologymedicine.medical_specialtyDose-Response Relationship Drugbusiness.industryVaginal trichomoniasisAdministration OralAntitrichomonal AgentsGeneral MedicineMiddle AgedTrichomonal VaginitisDermatologyTinidazoleAntitrichomonal agentchemistry.chemical_compoundchemistryNitroimidazolesmedicineHumansFemaleTrichomonas Vaginitisbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

2021

Abstract Aims Lomitapide is a lipid-lowering agent indicated as an adjunct therapy for adult homozygous familial hypercholesterolaemia (HoFH). This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe. Methods and results In a multicentre retrospective, observational study including 75 HoFH patients treated with lomitapide in a real-world clinical setting from 9 European countries, low-density lipoprotein cholesterol (LDL-C) changes, adverse events (AEs), and major adverse cardiovascular events (MACE) were assessed. After a median 19 months (interquartile range 11–41 months) of treatment with a mean dosage of 20 mg of lomitapide…

AdultHomozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaEpidemiologyAnticholesteremic AgentsHomozygoteMedium-term efficacyCholesterol LDLMedium-term safetyBenzimidazoleLomitapideHomozygous Familial Hypercholesterolemia; atherosclerosis; lomitapide; medium-term efficacy; medium-term safetyHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemiaRetrospective StudieAtherosclerosiAnticholesteremic AgentHumansBenzimidazolesatherosclerosisCardiology and Cardiovascular MedicineRetrospective StudiesHuman
researchProduct

Appropriateness of Therapeutic Drug Monitoring for Antidepressants in Routine Psychiatric Inpatient Care

2006

Although there is sufficient evidence of the benefits of therapeutic drug monitoring (TDM) for optimizing antidepressant therapy, its current use in routine care is far from optimal. As a prerequisite for developing improvement strategies, the appropriateness of TDM use was investigated in a psychiatric hospital in which TDM is applied routinely to a large extent. A retrospective analysis of all patients admitted in 2003 with a unipolar depressive disorder was performed. Based on detailed chart review, for all TDM tests, the time of blood sample taking in relation to the medication process and the consequences of the TDM results for clinical decision making were analyzed. Altogether, 748 pl…

AdultHospitals PsychiatricMalemedicine.medical_specialtyTime FactorsPsychological interventionMEDLINEQuality of life (healthcare)GermanyHumansMedicinePsychiatric hospitalPharmacology (medical)DosingPsychiatryAgedRetrospective StudiesAged 80 and overPharmacologyDepressive DisorderInpatient caremedicine.diagnostic_testbusiness.industryRetrospective cohort studyMiddle AgedAntidepressive AgentsTherapeutic drug monitoringQuality of LifeFemaleDrug MonitoringbusinessTherapeutic Drug Monitoring
researchProduct

Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission.

2019

Aims Non-adherence or partial adherence to psychotropic medication is found in 18-70% of patients. Many previously used methods for the assessment of adherence (e.g. questionnaires, pill counts, and electronic systems), however, might underreport actual rates of non-adherence to medication. The aim of this study was to quantify adherence using plasma level. Methods We conducted a 6-week prospective study of all consecutive admitted patients at the Paracelsus Medical University of Salzburg, Clinics of Psychiatry and Psychotherapy, who had been treated with antipsychotics/antidepressants prior to admission (pre-medication dosage in 161 of 233). Plasma drug levels were determined and compared …

AdultHospitals PsychiatricMalemedicine.medical_specialtymedicine.medical_treatmentMedication Adherence03 medical and health sciences0302 clinical medicinePharmacotherapyPatient AdmissionPrevalenceMedicineHumansDosingProspective StudiesAntipsychoticProspective cohort studyPsychiatrymedicine.diagnostic_testbusiness.industryMood DisordersGeneral NeuroscienceMental DisordersGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthNeurologyTherapeutic drug monitoringSchizophreniaPillSchizophreniaAntidepressantFemaleNeurology (clinical)business030217 neurology & neurosurgeryAntipsychotic AgentsPsychiatry and clinical neurosciences
researchProduct

Update on autoimmune hepatitis

2009

Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology that occurs in children and adults of all ages. Characteristics are its autoimmune features, hyperglobulinemia (IgG), and the presence of circulating autoantibodies, as well as a response to immunosuppressant drugs. Current treatment consists of prednisone and azathioprine and in most patients this disease has become very treatable. Over the past 2 years, a couple of new insights into the genetic aspects, clinical course and treatment of AIH have been reported, which will be the focus of this review. In particular, we concentrate on genome-wide microsatellite analysis, a novel mouse model of AIH, the evaluat…

AdultHyperglobulinemiaAzathioprineAutoimmune hepatitisDiseaseAntibodiesLiver diseaseLife ExpectancyAdrenal Cortex Hormonesimmune system diseasesPrednisonemedicineHumansSurvivorsChildHepatitisGenome Humanbusiness.industryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIThyroiditis AutoimmuneGastroenterologyAutoantibodyDNAGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneEditorialImmunoglobulin GImmunologybusinessImmunosuppressive AgentsMicrosatellite Repeatsmedicine.drugWorld Journal of Gastroenterology
researchProduct